{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:49:35Z","timestamp":1780645775971,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s41030-024-00269-9","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T16:02:06Z","timestamp":1726156926000},"page":"483-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-3928","authenticated-orcid":false,"given":"Christian","family":"Merlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2856-752X","authenticated-orcid":false,"given":"Teja","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-9184","authenticated-orcid":false,"given":"Lisa J.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina V.","family":"Scirica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian M.","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Muthukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime L.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alan","family":"Brookhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"1","key":"269_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65\u2013124.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"269_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0022-3476(97)70025-8","volume":"131","author":"M Corey","year":"1997","unstructured":"Corey M, Edwards L, Levison H, et al. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr. 1997;131(6):809\u201314.","journal-title":"J Pediatr"},{"issue":"01","key":"269_CR3","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/S1569-1993(09)60006-0","volume":"8 Suppl 1","author":"MW Konstan","year":"2009","unstructured":"Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros. 2009;8 Suppl 1(01):S15\u20139.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"269_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jcf.2010.04.002","volume":"9","author":"TG Liou","year":"2010","unstructured":"Liou TG, Elkin EP, Pasta DJ, et al. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros. 2010;9(4):250\u20136.","journal-title":"J Cyst Fibros"},{"key":"269_CR5","unstructured":"Vertex Pharmaceuticals Incorporated. Kalydeco (ivacaftor) [package insert]. 2012."},{"key":"269_CR6","unstructured":"Vertex Pharmaceuticals Incorporated. Kalydeco (ivacaftor) [package insert]. 2014."},{"key":"269_CR7","unstructured":"Vertex Pharmaceuticals Incorporated. Kalydeco (ivacaftor) [package insert]. 2023."},{"issue":"18","key":"269_CR8","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663\u201372.","journal-title":"N Engl J Med"},{"issue":"11","key":"269_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","volume":"187","author":"JC Davies","year":"2013","unstructured":"Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219\u201325.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"269_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","volume":"3","author":"RB Moss","year":"2015","unstructured":"Moss RB, Flume PA, Elborn JS, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(7):524\u201333.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"269_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","volume":"13","author":"K De Boeck","year":"2014","unstructured":"De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13(6):674\u201380.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"269_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1513\/AnnalsATS.201802-149OC","volume":"16","author":"L Kirwan","year":"2019","unstructured":"Kirwan L, Fletcher G, Harrington M, et al. Longitudinal trends in real-world outcomes after initiation of ivacaftor. A cohort study from the Cystic Fibrosis Registry of Ireland. Ann Am Thorac Soc. 2019;16(2):209\u201316.","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"269_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","volume":"192","author":"GS Sawicki","year":"2015","unstructured":"Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015;192(7):836\u201342.","journal-title":"Am J Respir Crit Care Med"},{"key":"269_CR14","doi-asserted-by":"publisher","unstructured":"Merlo CA, Thorat T, DerSarkissian M, et al. Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis. Thorax. 2024. https:\/\/doi.org\/10.1136\/thorax-2023-220558.","DOI":"10.1136\/thorax-2023-220558"},{"issue":"7","key":"269_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","volume":"13","author":"EA Knapp","year":"2016","unstructured":"Knapp EA, Fink AK, Goss CH, et al. The Cystic Fibrosis Foundation Patient Registry. Design and methods of a National Observational Disease Registry. Ann Am Thorac Soc. 2016;13(7):1173\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"269_CR16","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324\u201343.","journal-title":"Eur Respir J"},{"issue":"5","key":"269_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","volume":"6","author":"MA Brookhart","year":"2013","unstructured":"Brookhart MA, Wyss R, Layton JB, et al. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604\u201311.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"25","key":"269_CR18","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"key":"269_CR19","unstructured":"Food and Drug Administration. TRIKAFTA Prescribing Information. 2023."},{"issue":"3","key":"269_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","volume":"22","author":"T Lee","year":"2023","unstructured":"Lee T, Sawicki GS, Altenburg J, et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis. J Cyst Fibros. 2023;22(3):402\u20136.","journal-title":"J Cyst Fibros"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-024-00269-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:37:50Z","timestamp":1732034270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-024-00269-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["269"],"URL":"https:\/\/doi.org\/10.1007\/s41030-024-00269-9","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors received nonfinancial support (assistance with manuscript preparation) from Nucleus Global, which received funding from Vertex Pharmaceuticals Incorporated. Additional disclosures are as follows: Christian Merlo reports funding from Vertex Pharmaceuticals. Maral DerSarkissian, Catherine Nguyen, Yuqian M. Gu, and Aruna Muthukumar are current or former employees of Analysis Group Inc., which received research funding\/consultancy fees from Vertex Pharmaceuticals. Yuqian M. Gu is a current employee of Kaiser Permanente. M. Alan Brookhart has served as a scientific advisory committee member for Amgen, Atara Biotherapeutics, Brigham and Women\u2019s Hospital, Kite, Gilead, Intercept, NIDDK, and Vertex; he also has consulting fees\/equity from Target RWE and equity from VitriVax and Accompany Health. Christina V. Scirica, Teja Thorat, Lisa J. McGarry, Joe Healy, and Jaime L. Rubin are current or former employees of Vertex Pharmaceuticals Incorporated and may own stock or stock options in Vertex. Joe Healy is currently employed with Regeneron Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The US CFFPR protocol review committee provided feedback and approved the protocol with revisions prior to study start. The Advarra Institutional Review Board, which operates in accordance with the Helsinki Declaration of 1964 and its later amendments, granted an exemption for this research project based on the scope of the research in July 2020. All the patients in the CF registry provide informed consent to include their data in the registry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}